普遍预用药不影响向短效天冬酰胺酶的过渡或对聚乙二醇天冬酰胺酶过敏的发生率：单一机构的经验。

IF 0.8 4区医学 Q4 HEMATOLOGY

Journal of Pediatric Hematology/Oncology Pub Date : 2025-07-01 Epub Date: 2025-04-10 DOI:10.1097/MPH.0000000000003034

Lindsey A Murphy, Zanette K Bradley, Allie N Elozory, Dexiang Gao, Kelly E Faulk

{"title":"普遍预用药不影响向短效天冬酰胺酶的过渡或对聚乙二醇天冬酰胺酶过敏的发生率：单一机构的经验。","authors":"Lindsey A Murphy, Zanette K Bradley, Allie N Elozory, Dexiang Gao, Kelly E Faulk","doi":"10.1097/MPH.0000000000003034","DOIUrl":null,"url":null,"abstract":"Asparaginase is a critical component of therapy for acute lymphoblastic leukemia/lymphoma but is associated with hypersensitivity reactions. Severe reactions necessitate a transition to an Erwinia asparaginase product, which requires more frequent dosing and higher costs. Children's Hospital Colorado implemented universal pegaspargase premedication in May 2020 and a retrospective analysis was conducted to compare the rates of transition to Erwinia products and hypersensitivity reactions between the preimplementation and postimplementation cohorts. In this large single-institution experience, universal premedication did not impact rates of Erwinia transition or hypersensitivity reactions.","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":" ","pages":"e181-e186"},"PeriodicalIF":0.8000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Universal Premedication Does Not Impact Transition to Short-acting Asparaginase or Incidence of Hypersensitivity to Pegylated Asparaginase: A Single-institution Experience.\",\"authors\":\"Lindsey A Murphy, Zanette K Bradley, Allie N Elozory, Dexiang Gao, Kelly E Faulk\",\"doi\":\"10.1097/MPH.0000000000003034\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Asparaginase is a critical component of therapy for acute lymphoblastic leukemia/lymphoma but is associated with hypersensitivity reactions. Severe reactions necessitate a transition to an Erwinia asparaginase product, which requires more frequent dosing and higher costs. Children's Hospital Colorado implemented universal pegaspargase premedication in May 2020 and a retrospective analysis was conducted to compare the rates of transition to Erwinia products and hypersensitivity reactions between the preimplementation and postimplementation cohorts. In this large single-institution experience, universal premedication did not impact rates of Erwinia transition or hypersensitivity reactions.\",\"PeriodicalId\":16693,\"journal\":{\"name\":\"Journal of Pediatric Hematology/Oncology\",\"volume\":\" \",\"pages\":\"e181-e186\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pediatric Hematology/Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/MPH.0000000000003034\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/10 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pediatric Hematology/Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MPH.0000000000003034","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/10 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

天冬酰胺酶是治疗急性淋巴细胞白血病/淋巴瘤的关键成分，但与过敏反应有关。严重的反应需要过渡到Erwinia天冬酰胺酶产品，这需要更频繁的给药和更高的成本。科罗拉多州儿童医院于2020年5月实施了普遍的pegaspargase预用药，并进行了回顾性分析，以比较实施前和实施后队列之间过渡到Erwinia产品和超敏反应的比率。在这个大型单一机构的经验中，普遍的预用药没有影响欧文氏菌转化或超敏反应的发生率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Universal Premedication Does Not Impact Transition to Short-acting Asparaginase or Incidence of Hypersensitivity to Pegylated Asparaginase: A Single-institution Experience.

Asparaginase is a critical component of therapy for acute lymphoblastic leukemia/lymphoma but is associated with hypersensitivity reactions. Severe reactions necessitate a transition to an Erwinia asparaginase product, which requires more frequent dosing and higher costs. Children's Hospital Colorado implemented universal pegaspargase premedication in May 2020 and a retrospective analysis was conducted to compare the rates of transition to Erwinia products and hypersensitivity reactions between the preimplementation and postimplementation cohorts. In this large single-institution experience, universal premedication did not impact rates of Erwinia transition or hypersensitivity reactions.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Pediatric Hematology/Oncology 医学-小儿科

CiteScore

1.90

自引率

8.30%

发文量

415

审稿时长

2.5 months

期刊介绍： Journal of Pediatric Hematology/Oncology (JPHO) reports on major advances in the diagnosis and treatment of cancer and blood diseases in children. The journal publishes original research, commentaries, historical insights, and clinical and laboratory observations.